Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma

DOI Web Site Web Site 被引用文献3件

抄録

<jats:p>Several oncoproteins or tumor suppressor gene products have been indicated to be of value as predictors of the <jats:italic>de novo</jats:italic> resistance to cytotoxic agents. In this study, we have investigated the role of MDM2 (murine double minutes) overexpression in doxorubicin resistance of breast cancer. Immunocytochemical analysis demonstrated that MDM2‐positive tumors, even with p53‐negative pheno‐type, were significantly more resistant to doxorubicin treatment compared to MDM2‐negative tumors. An <jats:italic>in vitro</jats:italic> experimental model using stable <jats:italic>mdm2</jats:italic>‐transfected MCF‐7 cells carrying wild‐type p53 confirmed that the cells become approximately 3‐fold more resistant to doxorubicin as a result of MDM2 overexpression, and the wild‐type p53 function, such as the induction of p21<jats:sup>Waf1</jats:sup> following DNA damage, was significantly suppressed. MDM2 overexpression is suggested to be a novel marker for predicting lack of response to doxorubicin treatment in breast cancer patients.</jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

キーワード

問題の指摘

ページトップへ